Skip to content

D&A at other companies

Insulet logo
InsuletPODD
$26.2M+20.7%
Tandem Diabetes Care logo
Tandem Diabetes CareTNDM
$4.5M+4.5%
Medtronic logo
MedtronicMDT
$716M-14.8%
Lifecore Biomedical, Inc. logo
Lifecore Biomedical, Inc.LFCR
$2.31M+20.7%
Mannkind logo
MannkindMNKD
$6.38M+203%
Beta Bionics, Inc. Common Stock logo
Beta Bionics, Inc. Common StockBBNX
$585K+93.1%

Other financials

Income statement

See full
Revenue$221.8M-14.4%
Gross profit$127.8M-22.1%
Operating income$35.0M-44.4%
Net income-$4.1M-117%
EPS (diluted)-$0.07-118%

Balance sheet

See full
Cash & equivalents$193.4M-8.9%
Total debt$1.4B-12.5%
Total equity-$626.1M+15.0%
Total assets$1.0B-8.1%

Cash flow

See full
Operating cash flow$31.1M-2.2%
CapEx$500.0K+400%
Free cash flow$30.6M-3.5%

Valuation

See full
Market cap$193.41M-64.3%
Enterprise value$1.37B-24.8%
P/E1.7×-4.8×
P/S0.2×-0.3×

Profitability

See full
Gross margin61.9%-1.6pp
Operating margin25.8%+9.7pp
Net margin10.7%+5.8pp
FCF margin19.6%+16.0pp

Returns & leverage

See full
Return on equity71.9%
Debt / equity
Current ratio2.5×0.0×

Where this comes from

Reported directly by Embecta Corp. in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The official record: Embecta Corp.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Embecta Corp.'s d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Embecta Corp.'s D&A?
Embecta Corp. (EMBC) reported D&A of $10.2M in Q1 2026.
How has Embecta Corp.'s D&A changed year-over-year?
Embecta Corp.'s D&A increased by 13.3% year-over-year, from $9M to $10.2M.
What is the long-term trend for Embecta Corp.'s D&A?
Over 4 years (2021 to 2025), Embecta Corp.'s D&A has grown at a 1.5% compound annual growth rate (CAGR), from $38.3M to $40.7M.
What does D&A mean?
Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.